Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1259 • ACR Convergence 2024
Adverse Childhood Experiences Are Associated with Patient-Reported Outcomes in Adolescents and Young Adults with Systemic Lupus
Tamar Rubinstein¹, Avni Dave², Terrence Calistro³, Kimberly Rapoza³, Shari Salzhauer Berkowitz³, Joyce Hui-Yuen⁴, Zanab Mian⁵, Emily Masi⁶ and Kathleen Kenney-Riley⁷, ¹Albert Einstein College of Medicine, White Plains, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Mercy University, Dobbs Ferry, NY, ⁴Northwell Health, Cohen Children's Medical Center, Great Neck, NY, ⁵Cohen Children's Medical Center, Lake Success, NY, ⁶Cohen Children's Medical Center, Floral Park, NY, ⁷Albert Einstein College of Medicine, Port Chester, NY
Background/Purpose: Adverse childhood experiences (ACEs), are major life stressors that occur before the age of 18 and include experiences of household dysfunction. Recently, prior trauma,…
Abstract Number: 1404 • ACR Convergence 2024
Modeling Diversity in Systemic Lupus Erythematosus (SLE) Clinical Trials Using Real-world Data (RWD) Sources
Andrew Bevan¹ and Nora Carroll², ¹Integrated Project Solutions, PPD, part of Thermo Fisher Scientific, Cambridge, United Kingdom, ²Cardiovascular and General Medicine, Thermo Fisher Scientific, Athlone, Ireland
Background/Purpose: The FDA places emphasis on studying clinically relevant trial populations but does not address how these might be defined. SLE disproportionately affects women and…
Abstract Number: 1499 • ACR Convergence 2024
Outcome of Newly Onset SLE with Neuropsychiatric Symptoms and Its Clinical Features in Daily Clinical Practice: A Single Center Study
Shuzo Sato, Fumitaka Seike, Yuya Sumichika, Kenji Saito, Shuhei Yoshida, Haruki Matsumoto, Jumpei Temmoku, Yuya Fujita, Naoki Matsuoka and Tomoyuki Asano, Fukushima Medical University, Fukushima, Fukushima, Japan
Background/Purpose: Although neuropsychiatric (NP) symptoms may occur in patients with SLE even in initial onset, studies regarding the distinct clinical features of SLE patients with…
Abstract Number: 1515 • ACR Convergence 2024
Incidence and Predictors of Neuropsychiatric Lupus—a Contemporary Cohort Study Across the United States
Yomaira Silva¹, Baijun Zhou¹, Grace Haeun Lee¹, Kila Panchot¹, Hyon K. Choi² and April Jorge³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Lexington, MA, ³Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with SLE can experience a variety of neuropsychiatric manifestations across 19 recognized syndromes (1999 ACR Nomenclature). Studies of neuropsychiatric SLE (NPSLE) have been…
Abstract Number: 1532 • ACR Convergence 2024
Not yet on Track: Retrospective Chart Analysis Reveals Physician’s Treatment Approaches in SLE Fall Short of New EULAR Guidance
Maxine Yarnall¹, Ryan Rex² and Sawyer May¹, ¹Spherix Global Insights, Exton, PA, ²Spherix Global Insights, Chester Springs, PA
Background/Purpose: In October 2023, EULAR released updated recommendations for the management of SLE2. Notably, since the previous guidelines update in 2019, anifrolumab received approval for…
Abstract Number: 1552 • ACR Convergence 2024
Kinetics of Mucocutaneous and Musculoskeletal Responses to Deucravacitinibin Patients with Active SLE in the Phase 2 PAISLEY Trial
Ronald Van Vollenhoven¹, Joseph Merola², Kathryn H. Dao³, Piotr Leszczynski⁴, Marilyn Pike⁵, Samantha Pomponi⁶, Coburn Hobar⁶, Matthew J. Colombo⁶, Ravi Koti⁶, Subhashis Banerjee⁶, Thomas Wegman⁷ and Eric Morand⁸, ¹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ²UT Southwestern Medical Center, Newton, MA, ³Department of Internal Medicine, Division of Rheumatology, The University of Texas Southwestern Medical Center, Dallas, ⁴Department of Internal Medicine, Poznań University of Medical Sciences, Poznań, Poland, ⁵Rheumatology, MedPharm Consulting, Inc., Raleigh, NC, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Beaver Falls, PA, ⁸School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: Deucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of moderate to severe plaque…
Abstract Number: 1703 • ACR Convergence 2024
Single Cell and Spatial Transcriptomics Implicate Vascular Cell Orchestration of Inflammatory Changes After Ultraviolet Light Exposure
Rachael Wasikowski¹, Erin Theisen², Jie An³, Lam C. Tsoi¹, Ksenia Anufrieva⁴, Kevin Wei⁵, Johann Gudjonsson⁶ and Keith Elkon³, ¹Michigan, Dept. of Dermatology, Ann Arbor, MI, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³University of Washington, Seattle, WA, ⁴BWH, Cambridge, MA, ⁵Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁶University of Michigan, Ann Arbor, MI
Background/Purpose: Skin sensitivity to sunlight affects ~70% of systemic lupus erythematosus (SLE). In addition, ultraviolet radiation (UVR) can stimulate systemic disease flares, but how this…
Abstract Number: 1786 • ACR Convergence 2024
Select Immune Cell Dysregulation Identifies Clinically Quiescent Patients at Risk of Flare Who Stop Mycophenolate Mofetil While Continuing Hydroxychloroquine
Christian Wright¹, Rufei Lu², Catriona Wagner³, Carla Guthridge⁴, Susan Macwana¹, Eliza Chakravarty⁴, Tammy Utset⁵, Diane Kamen⁶, Gabriel Nicolas Contreras Martin⁷, William McCune⁸, Cynthia Aranow⁹, Kenneth Kalunian¹⁰, Elena Massarotti¹¹, Megan Clowse¹², Brad Rovin¹³, S. Sam Lim¹⁴, Vikas Majithia¹⁵, Richard Looney¹⁶, Maria Dall'Era¹⁷, Doruk Erkan¹⁸, Amit Saxena¹⁹, Nancy Olsen²⁰, Kichul Ko²¹, Ellen Goldmuntz²², William Barry²³, Ashley Pinckney²⁴, ALE06 Clinical Study Team⁴, Judith James⁴ and Joel Guthridge⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, ²University of California San Francisco, San Bruno, CA, ³Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Chicago, Chicago, IL, ⁶Medical University of South Carolina, Charleston, SC, ⁷University of Miami, Key Biscayne, FL, ⁸U Michigan, Ann Arbor, MI, ⁹Feinstein Institutes for Medical Research, New York, NY, ¹⁰University of California San Diego, La Jolla, CA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²Duke University, Chapel Hill, NC, ¹³The Ohio State University, Columbus, OH, ¹⁴Emory University, Atlanta, GA, ¹⁵Mayo Clinic Florida, Jacksonville, FL, ¹⁶University of Rochester, Rochester, NY, ¹⁷UCSF, Corte Madera, CA, ¹⁸Hospital for Special Surgery, New York, NY, ¹⁹NYU School of Medicine, New York, NY, ²⁰Penn State University/Milton S Hershey, Hershey, PA, ²¹The University of Chicago, Chicago, IL, ²²NIAID/ NIH, Washington, DC, ²³Rho, Inc, Durham, NC, ²⁴Rho, St Louis Park, NC
Background/Purpose: Mycophenolate mofetil (MMF) is commonly used to treat major SLE manifestations; however, it is associated with significant toxicities. Thus, MMF withdrawal is desirable in…
Abstract Number: 1806 • ACR Convergence 2024
Bisphenol a Methylation Scores Associate with SLE and ClinicalSubphenotypes
Holme Vestin¹, Nina Oparina², Maija-Leena Eloranta¹, Martina Frodlund³, Iva Gunnarsson⁴, Christopher Sjowall⁵, Elisabet Svenungsson⁶, Lars Rönnblom¹, Ann-Christine Syvänen¹, Johanna Sandling¹, Juliana Imgenberg-Kreuz¹ and Dag Leonard¹, ¹Uppsala university, Uppsala, Sweden, ²UU, Uppsala, Sweden, ³Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁴Karolinska Institute, Stockholm, Sweden, ⁵Linköping University, Linköping, Sweden, ⁶Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by production of auto-antibodies, immune complex formation and an activated type I interferon system. Both genetic and environmental…
Abstract Number: 1945 • ACR Convergence 2024
The Bridge to Adult Care from Childhood for Young Adults with Rheumatic Disease (BACC YARD) Program, a Pediatric-to-Adult Rheumatology Transition Program: 2024 Updates
John Bridges¹, Eileen Rife², Randy Cron³, Livie Timmerman⁴, Linda McAllister⁵, Annelle Reed⁶, Carolyn Smith⁷, Emily Smitherman³, Matthew Stoll³, Bethany Walker⁵ and Melissa Mannion³, ¹University of Alabama at Birmingham/Children's of Alabama, Birmingham, AL, ²University of Alabama Birmingham, Vestavia Hills, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama at Birmingham, Gardendale, AL, ⁵Children's of Alabama, Trussville, AL, ⁶Children's of Alabama, Tuscaloosa, AL, ⁷Children's of Alabama, Birmingham, AL
Background/Purpose: The transition period from pediatric to adult-oriented rheumatology care is a high-risk time for disease flare and poor outcomes. We previously demonstrated implementation of…
Abstract Number: 2371 • ACR Convergence 2024
The Role of Intracytoplasmic Toll- Like Receptors (TLR) and MyD88 in B Cell Subsets as Renal Response Predictors in Patients with Lupus Nephritis
Fabiola Cassiano-Quezada¹, José Jiram Torres-Ruiz², Jennifer Balderas Miranda³, José Luis Maravillas-Montero⁴, Karina Santana-de Anda², Beatriz Alcalá-Carmona⁵, Nancy R Mejía-Domínguez⁵, Yatzil Reyna-Juárez⁵, María José Ostos-prado⁵, Guillermo Juarez-Vega⁴ and Diana Gomez-martin⁶, ¹Department of Internal Medicine. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ²Departament of Immunology and Rheumatology. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, ³Universidad Nacional Autónoma de México, Ciudad de México, Mexico, ⁴Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁵Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ⁶INCMNSZ, Mexico City, Federal District, Mexico
Background/Purpose: Recently, a gain of-function mutation within TLR7 was identified to induce SLE in a murine model and increased the survival of activated B lymphocytes,…
Abstract Number: 2388 • ACR Convergence 2024
Racial/Ethnic Variation in Multimorbidity Risk and Accrual and Comorbid Conditions Among Patients with Systemic Lupus Erythematosus
Katrina Williamson¹, Herbert Heien², Maria Stevens², Cynthia Crowson², Rozalina McCoy² and Ali Duarte-Garcia², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have been shown to have increased burden of multimorbidity. Racial disparities in multimorbidity have also been shown repeatedly.…
Abstract Number: 2408 • ACR Convergence 2024
Impact of Pain and Fatigue on Quality of Life Among Patients with Systemic Lupus Erythematosus
Amanda Eudy¹, Megan Clowse², Meenakshi Jolly³, David Pisetsky⁴, Kai Sun⁵, Rebecca Sadun⁵, Lisa Criscione-Schreiber⁶, Mithu Maheswaranathan⁶, Jayanth Doss⁵ and Jennifer Rogers⁶, ¹Duke University, Raleigh, NC, ²Duke University, Chapel Hill, NC, ³Rush University Medical Center, Chicago, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Durham, NC, ⁶Duke University, Durham
Background/Purpose: Our prior qualitative work discovered a subgroup of patients with SLE who experience persistent symptoms of fatigue and widespread pain, even on self-described “good…
Abstract Number: 2424 • ACR Convergence 2024
Anifrolumab Effects on Response to Influenza Vaccine in SLE
Cristina Arriens¹, Anca Askanase², Wambui Machua³, Fotios Koumpouras⁴, Ken Smith¹, Joel Guthridge¹, Judith James¹ and Joan Merrill⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Columbia University Medical Center, New York, NY, ³Piedmont Hospital Center, Atlanta, GA, ⁴Yale School of Medicine, New Haven, CT, ⁵Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: Risk for infections in systemic lupus may arise from immunosuppressant treatments or intrinsic immune defects. Disordered interferon signals are a hallmark of SLE. Anifrolumab, which…
Abstract Number: 2545 • ACR Convergence 2024
Phosphodiesterase 1B Contributes to Neuropsychiatric Manifestations in Lupus-Prone Mice Through Microglial Activation
Shuhei Takeyama¹, Michihito Kono¹, Kohei Karino¹, Yuki Kudo¹, Masatoshi Kanda², Hiroyuki Nakamura², Kenichi Miyamoto¹, Kazuro Kamada³, Maria Tada¹, Ryo Hisada¹, Yuichiro Fujieda¹, Masaru Kato¹, Olga Amengual⁴ and Tatsuya Atsumi¹, ¹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ²Department of Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan, Sapporo, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapprp, Japan, ⁴Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) is one of the most severe organ manifestations in SLE and is associated with poor quality of life. We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].